Resource Summary Report

Generated by NIF on Apr 27, 2025

Phoenix

RRID:SCR_003163
Type: Tool

Proper Citation

Phoenix (RRID:SCR_003163)

Resource Information

URL: http://www.stanford.edu/group/nolan/retroviral_systems/phx.html

Proper Citation: Phoenix (RRID:SCR_003163)

Description: A second-generation retrovirus producer lines for the generation of helper free ecotropic and amphotropic retroviruses. The lines are based on the 293T cell line (a human embryonic kidney line transformed with adenovirus E1a and carrying a temperature sensitive T antigen co-selected with neomycin). The unique feature of this cell line is that it is highly transfectable with either calcium phosphate mediated transfection or lipid-based transfection protocols-- up to 50% or higher of cells can be transiently transfected. The lines were created by placing into 293T cells constructs capable of producing gag-pol, and envelope protein for ecotropic and amphotropic viruses. The lines offered advantages over previous stable systems in that virus can be produced in just a few days. Academic and non-profit laboratories may obtain the Phoenix cells from either Allele Biotechnology or the National Gene Vector Bank. The vectors may be obtained from Addgene. They are no longer distributing these reagents from the lab.

Abbreviations: Phoenix

Synonyms: Phoenix helper, Phoenix system

Resource Type: biomaterial supply resource, material resource, cell repository

Keywords: retrovirus, episome, producer line, cell line, vector

Funding:

Resource Name: Phoenix

Resource ID: SCR_003163

Alternate IDs: nlx_156864

Record Creation Time: 20220129T080217+0000

Record Last Update: 20250426T055612+0000

Ratings and Alerts

No rating or validation information has been found for Phoenix.

No alerts have been found for Phoenix.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 2812 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF.

Sangana R, et al. (2025) Pharmacokinetics of Ganaplacide and Lumefantrine in Adults, Adolescents, and Children with Plasmodium falciparum Malaria Treated with Ganaplacide Plus Lumefantrine Solid Dispersion Formulation: Analysis of Data from a Multinational Phase 2 Study. Journal of clinical pharmacology, 65(2), 179.

Bowman EA, et al. (2025) Invasive Buffelgrass, Cenchrus ciliaris, Balances Opportunistic Acquisition of Foliar fungi With Host and Environmental Filtering in Its Introduced Range. Molecular ecology, 34(2), e17609.

Mao X, et al. (2025) A phase I, randomized, placebo-controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults. Clinical and translational science, 18(1), e70095.

Liu P, et al. (2025) Discovery of a common light chain bispecific antibody targeting PD-1 and PD-L1 by Hybridoma-to-Phage-to-Yeast (H2PtY) platform. Antibody therapeutics, 8(1), 1.

Blood AJ, et al. (2025) Integrating Ambulatory Care Pharmacists Into Value-Based Primary Care: A Scalable Solution to Chronic Disease. Journal of primary care & community health, 16, 21501319241312041.

AnandaKumar SR, et al. (2025) Bioavailability study of enantiopure (S)-Equol in CD(SD)IGS rats. Scientific reports, 15(1), 3141.

Liu H, et al. (2025) Development and Evaluation of Aloperine-Loaded Nanostructured Lipid Carriers for the Treatment of Pulmonary Arterial Hypertension. International journal of nanomedicine, 20, 871.

Cui J, et al. (2025) Mitochondrial Genome Insights into Evolution and Gene Regulation in Phragmites australis. International journal of molecular sciences, 26(2).

van der Plas M, et al. (2025) Effects of GLPG3970 on Sulfasalazine and Methotrexate Pharmacokinetics in Healthy Adults: Two Open-Label, Phase I, Drug-Drug Interaction Studies. Clinical pharmacology and therapeutics, 117(2), 427.

Tremblay SM, et al. (2025) Services Addressing Mental Health Needs of Youth in Physical Rehabilitation: Perspectives of Clinicians, Youth and Family Members. Child: care, health and development, 51(1), e70019.

Brimhall DB, et al. (2025) Transfer of the Oral Gonadotropin-Releasing Hormone Receptor Antagonist Relugolix Into Breast Milk of Healthy Lactating Women. Pharmacology research & perspectives, 13(1), e70067.

Kwak H, et al. (2025) GC1126A, a novel ADAMTS13 mutein, evades autoantibodies in immune-mediated thrombotic thrombocytopenic purpura. Scientific reports, 15(1), 1613.

Okwumabua O, et al. (2025) Detection of SARS-CoV-2 and a possible variant in shelter cats. PloS one, 20(1), e0317104.

Ishikawa Y, et al. (2025) Real-world comparative outcomes and toxicities after definitive radiotherapy using proton beam therapy versus intensity-modulated radiation therapy for prostate cancer: a retrospective, single-institutional analysis. Journal of radiation research, 66(1), 39.

Roell W, et al. (2025) Characterization of LY3324954 a long-acting glucagon-receptor agonist. Molecular metabolism, 91, 102073.

Mickelson KD, et al. (2025) A Retrospective Analysis Evaluating the Impact of Neighborhood Deprivation on Birth Weight in Phoenix, Arizona. International journal of environmental research and public health, 22(1).

Hybholt M, et al. (2025) Emotional Reflexivity and Lifelong Leisure Time Physical Activity: Managing 'Successful Womanhood' for Busy Middle-Class Women. Sociology of health & illness, 47(2), e70004.

Vuppalanchi R, et al. (2025) Pharmacokinetic, Safety, and Pharmacodynamic Profiles of Saroglitazar Magnesium in Cholestatic Cirrhosis With Hepatic Impairment and Participants With Renal Impairment. Clinical pharmacology and therapeutics, 117(1), 240.

Cipriano A, et al. (2025) Time Course of Reversal of Fentanyl-Induced Respiratory Depression in Healthy Subjects by Intramuscular Nalmefene and Intramuscular and Intranasal Naloxone. Journal of clinical pharmacology, 65(2), 206.

Anttinen M, et al. (2025) Salvage Magnetic Resonance Imaging-guided Transurethral Ultrasound Ablation for Localized Radiorecurrent Prostate Cancer. European urology open science, 71, 69.